Trial Access Available to Investors
If you are an investor and would like to explore our research, we are pleased to offer complimentary two-week trial access to our Basic content, subject to a trial agreement.
If you are an investor and would like to explore our research, we are pleased to offer complimentary two-week trial access to our Basic content, subject to a trial agreement.
Looking at US BSL CLO BB tranches traded via BWICs since 14 April 2026, the graph below summarises DM cover levels (or best levels where DNT), grouped by manager tier and MVOC range for deals with reinvestment periods ending in 2029–2031.
A sample of 1,664 US BSL CLO deals (vintage 2013–1H 2025) is included in this study. Deals with a collateral pool factor below 55% are excluded.
Just as the first signs of spring draw people out into the streets, an improving trading backdrop, combined with post-April payment dates, brought a wave of equity tranches into BWIC last week, with every tranche trading with released covers.
Just as the first signs of spring draw people out into the streets, an improving trading backdrop, combined with post-April payment dates, brought a wave of equity tranches into BWIC last week, with every tranche trading with released covers.
Among the 2012–2021 vintages, only 1.8% of EU CLO BB tranches show an MVOC below 100%, compared with 15.5% or US BSL CLOs. Meanwhile, 19.0% of US BSL deals report negative equity NAV, versus 15.4% for EU CLO deals.
